Entera Bio to Engage at Notable Healthcare Conference
Entera Bio Ltd. (NASDAQ: ENTX), a pioneering company in oral peptide and protein replacement therapies, is set to participate in the 8th Annual Evercore ISI Healthcare Conference. This event, hosted annually, brings together key stakeholders in the healthcare industry to discuss innovations and strategies. Miranda Toledano, the Company’s Chief Executive Officer, will lead a fireside chat that promises to offer intriguing insights into Entera's progress and future directions.
Conference Details and Participation Overview
The fireside chat is scheduled for December 3rd from 9:10 AM to 9:30 AM. The event will take place in person at Sevilla A. This conference runs from December 3 to 5, gathering industry leaders, investors, and healthcare professionals to network and exchange ideas. Attendees will have the opportunity to learn more about Entera's innovative approaches to addressing significant unmet medical needs.
Webcast Access and Event Replay
A live webcast of the discussion will be available, providing easy access for those unable to attend in person. Furthermore, a recorded version of the session will remain accessible for 90 days post-event, ensuring that all interested parties can stay informed about Entera's latest developments.
Highlighting Entera Bio’s Innovations
Entera Bio is recognized for its commitment to addressing significant medical needs through innovative oral treatments. Their proprietary N-Tab™ technology facilitates the development of oral peptide therapies that can transform existing treatment paradigms. Currently, Entera's main focus includes products targeting osteoporosis and metabolic disorders, aiming to enhance patient compliance and improve health outcomes.
Advancements in Drug Development
One of Entera's most promising candidates, EB613 (oral PTH(1-34)), is being evaluated as a groundbreaking option for post-menopausal women experiencing low bone mineral density (BMD). The Company recently completed a placebo-controlled Phase 2 study demonstrating significant results regarding bone turnover markers and BMD enhancement, highlighting the potential of EB613 to be the first oral treatment in its class.
Partnerships and Future Directions
Alongside its peptide therapies, Entera Bio is collaborating with OPKO Health on developing the first oral GLP-2 peptide. This innovative approach seeks to provide injection-free alternatives for patients with rare malabsorption conditions, addressing critical gaps in current treatment offerings. As Entera continues to advance its pipeline and cultivate strategic partnerships, the company positions itself at the forefront of the healthcare landscape.
Conclusion: Entera Bio's Commitment to Transformative Therapies
With its presence at the Evercore ISI Healthcare Conference, Entera Bio reinforces its commitment to transforming treatment for chronic conditions through innovative oral therapies. As the healthcare sector evolves, the insights shared during this event will likely illuminate the path forward for both Entera and the large patient populations it aims to serve.
Frequently Asked Questions
What is the purpose of Entera Bio’s participation in the conference?
The participation aims to showcase Entera's innovations and advancements in oral peptide therapies to industry professionals and investors.
When and where is the conference held?
The conference is scheduled for December 3-5 and will take place in Sevilla A.
Who will represent Entera at the conference?
CEO Miranda Toledano will represent Entera Bio during the fireside chat.
How can attendees access the discussions?
A live webcast will be available, with a replay that remains accessible for 90 days following the event.
What are some key developments for Entera Bio?
Entera Bio has made significant progress with its candidate EB613 for osteoporosis and other innovative therapies targeting metabolic disorders.
